We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
For investors seeking momentum, Health Care Select Sector SPDR Fund (XLV - Free Report) is probably on radar. The fund just hit a 52-week high and is up 13% from its 52-week low price of $122.59/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed:
XLV in Focus
Health Care Select Sector SPDR Fund targets the broader healthcare sector. Pharma takes the largest share at 30.3% from a sector look, while healthcare providers and services, healthcare equipment and supplies, biotech and life sciences tools & services have double-digit exposure each. XLV charges 10 bps in annual fees (read: all the Healthcare ETFs here).
Why the Move?
The healthcare sector has been an area to watch lately, given that the strong optimism in the U.S. stock market has started to falter. Healthcare generally outperforms during periods of low growth and high uncertainty. Additionally, investors are in search of cheap stocks for their portfolios after a huge surge in 2023. Healthcare stocks didn’t explode much last year amid the broad market rally.
More Gains Ahead?
Currently, XLV has a Zacks ETF Rank #1 (Strong Buy) with a Medium risk outlook, suggesting that the outperformance could continue in the months ahead. However, many spaces that make up this ETF have a strong Zacks Industry Rank. So, there is definitely some promise for those who want to ride this surging ETF a little further.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Healthcare ETF (XLV) Hits New 52-Week High
For investors seeking momentum, Health Care Select Sector SPDR Fund (XLV - Free Report) is probably on radar. The fund just hit a 52-week high and is up 13% from its 52-week low price of $122.59/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed:
XLV in Focus
Health Care Select Sector SPDR Fund targets the broader healthcare sector. Pharma takes the largest share at 30.3% from a sector look, while healthcare providers and services, healthcare equipment and supplies, biotech and life sciences tools & services have double-digit exposure each. XLV charges 10 bps in annual fees (read: all the Healthcare ETFs here).
Why the Move?
The healthcare sector has been an area to watch lately, given that the strong optimism in the U.S. stock market has started to falter. Healthcare generally outperforms during periods of low growth and high uncertainty. Additionally, investors are in search of cheap stocks for their portfolios after a huge surge in 2023. Healthcare stocks didn’t explode much last year amid the broad market rally.
More Gains Ahead?
Currently, XLV has a Zacks ETF Rank #1 (Strong Buy) with a Medium risk outlook, suggesting that the outperformance could continue in the months ahead. However, many spaces that make up this ETF have a strong Zacks Industry Rank. So, there is definitely some promise for those who want to ride this surging ETF a little further.